Literature DB >> 34096047

Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia.

Adrianne Rasche1,2, Emily F Mason2,3, Stephen A Strickland2,4, Michael Byrne2,4, P Brent Ferrell2,4.   

Abstract

Entities:  

Keywords:  Keywords: acute myeloid leukaemia; acute myeloid leukemia; differentiation; differentiation.; haematopoietic cell transplant; hematopoietic cell transplant; isocitrate dehydrogenase inhibitor

Mesh：

Substances：

Year:  2021        PMID： 34096047      PMCID： PMC8936480          DOI： 10.1111/bjh.17573

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   8.615


× No keyword cloud information.
  6 in total

1.  Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.

Authors:  K C Birendra; Courtney D DiNardo
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-05-05

2.  The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.

Authors:  Michael Byrne; Nathalie Danielson; Salyka Sengsayadeth; Adrianne Rasche; Katie Culos; Katie Gatwood; Houston Wyatt; Wichai Chinratanalab; Bhagirathbhai Dholaria; P Brent Ferrell; Kristin Fogo; Stacey Goodman; Madan Jagasia; Reena Jayani; Adetola Kassim; Sanjay R Mohan; Bipin N Savani; Stephen A Strickland; Brian G Engelhardt; Michael Savona
Journal:  Am J Hematol       Date:  2020-06-15       Impact factor: 10.047

3.  Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

Authors:  Courtney D DiNardo; Eytan M Stein; Stéphane de Botton; Gail J Roboz; Jessica K Altman; Alice S Mims; Ronan Swords; Robert H Collins; Gabriel N Mannis; Daniel A Pollyea; Will Donnellan; Amir T Fathi; Arnaud Pigneux; Harry P Erba; Gabrielle T Prince; Anthony S Stein; Geoffrey L Uy; James M Foran; Elie Traer; Robert K Stuart; Martha L Arellano; James L Slack; Mikkael A Sekeres; Christophe Willekens; Sung Choe; Hongfang Wang; Vickie Zhang; Katharine E Yen; Stephanie M Kapsalis; Hua Yang; David Dai; Bin Fan; Meredith Goldwasser; Hua Liu; Sam Agresta; Bin Wu; Eyal C Attar; Martin S Tallman; Richard M Stone; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2018-06-02       Impact factor: 91.245

4.  A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML.

Authors:  Emily F Mason; Olga Pozdnyakova; Mikhail Roshal; Amir T Fathi; Eytan M Stein; P Brent Ferrell; Aaron C Shaver; Mark Frattini; Hongfang Wang; Lei Hua; Jimmy Mu; Sung Choe; Rengyi Xu; Caroline Almon; Michael Cooper; Richard M Stone; Robert P Hasserjian; Michael R Savona
Journal:  Blood Adv       Date:  2021-04-27

5.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Authors:  Eytan M Stein; Courtney D DiNardo; Daniel A Pollyea; Amir T Fathi; Gail J Roboz; Jessica K Altman; Richard M Stone; Daniel J DeAngelo; Ross L Levine; Ian W Flinn; Hagop M Kantarjian; Robert Collins; Manish R Patel; Arthur E Frankel; Anthony Stein; Mikkael A Sekeres; Ronan T Swords; Bruno C Medeiros; Christophe Willekens; Paresh Vyas; Alessandra Tosolini; Qiang Xu; Robert D Knight; Katharine E Yen; Sam Agresta; Stephane de Botton; Martin S Tallman
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

6.  Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.

Authors:  Michael D Amatangelo; Lynn Quek; Alan Shih; Eytan M Stein; Mikhail Roshal; Muriel D David; Benoit Marteyn; Noushin Rahnamay Farnoud; Stephane de Botton; Olivier A Bernard; Bin Wu; Katharine E Yen; Martin S Tallman; Elli Papaemmanuil; Virginie Penard-Lacronique; Anjan Thakurta; Paresh Vyas; Ross L Levine
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.